PIPELINE
Therapeutics in development with the potential to treat deadly cancers.
Lumigen is advancing a pipeline of antibody-guided nanocomplex therapeutics built on its proprietary NOVVA™ platform. Each NOVVA™ is designed to target a specific cancer receptor and deliver a high, localized drug payload directly into tumor cells. This modular architecture enables rapid adaptation across multiple tumor types and payloads while maintaining a common development framework.
| Program | Target Indication | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
LUM-001 Fn14-targeted NOVVA™ |
Fn14-positive solid tumors |
-
Therapeutic Area: Fn14+ Solid Tumors
Program Overview: Our first-in-class lead program, LUM-001, demonstrates NOVVA’s potential in multiple cancers including glioblastoma and triple-negative breast cancer (TNBC). IND-enabling work is underway with regulatory alignment planned through the FDA INTERACT process.
LUM-001 is a first-in-class, Fn14-targeted nanocomplex built on Lumigen’s proprietary NOVVA™ platform. Fn14 is a receptor that is highly expressed in many aggressive cancers including glioblastoma, triple negative breast cancer, pancreatic cancer, and other difficult-to-treat tumors, while being rare in normal tissue. This makes it a powerful new portal for targeted therapy. LUM-001 delivers high-dose paclitaxel, a chemotherapy, directly to tumors and is designed to overcome the barriers that block most therapies from reaching and penetrating solid tumors.
LUM-001 is currently in development for advanced triple negative breast cancer, where it has shown extended survival in multiple preclinical models compared to the current standard of care. It has also demonstrated efficacy in preclinical models of glioblastoma, supporting its potential as a treatment for both primary brain tumors and other Fn14-positive cancers.